SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases

(2021) Charles Khouri et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Atrial Fibrillation

(2021) Gregory F. Michaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

(2020) Salva R. Yurista et al.   Cardiovascular Diabetology

Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial

(2020) Thomas A. Zelniker et al.   CIRCULATION

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence

(2020) Benedetta Maria Bonora et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database

(2020) Putkaradze Zaza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction

(2020) Xiaodong Peng et al.   Frontiers in Physiology

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials

(2020) Wen-jie Li et al.   Cardiovascular Diabetology

Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK

(2020) Ling Xiao et al.   CIRCULATION

Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials

(2020) Victor Okunrintemi et al.   DIABETES OBESITY & METABOLISM

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease

(2020) Basile Chrétien et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus

(2019) David D. Berg et al.   CIRCULATION

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

(2019) Qingmiao Shao et al.   Cardiovascular Diabetology

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors

(2019) Gian Paolo Fadini et al.   BMJ Open Diabetes Research & Care

Observational research on sodium glucose co-transporter 2 inhibitors: a real breakthrough?

(2018) Emanuel Raschi et al.   DIABETES OBESITY & METABOLISM

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems

(2018) E. Raschi et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions

(2018) Gian Paolo Fadini et al.   Diabetes Therapy

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions

(2018) Gian Paolo Fadini et al.   Diabetes Therapy

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

(2017) Kåre I Birkeland et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

(2016) F. Zaccardi et al.   DIABETES OBESITY & METABOLISM

Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data

(2016) Mayur Sarangdhar et al.   NATURE BIOTECHNOLOGY

A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases

(2015) Mickael Arnaud et al.   DRUG SAFETY

Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies

(2015) Christos A. Goudis et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records

(2012) M. Liu et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Meta-Analysis of Cohort and Case–Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial Fibrillation

(2011) Rachel R. Huxley et al.   AMERICAN JOURNAL OF CARDIOLOGY

Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation

(2011) Alvaro Alonso et al.   CIRCULATION

Prevention of Atrial Fibrillation

(2009) Emelia J. Benjamin et al.   CIRCULATION

Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation

(2009) G. A. Nichols et al.   DIABETES CARE